These are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabilities across all the value chain, starting from early research to commercialization.”
Speaking to Scrip last month, he said that since becoming CEO (permanently since February 2023), “we made sure we did the right investments to maximize the potential of our biologics in Europe but also, importantly, create an innovation machine in our R&D center for the future